Cardiology overview cardiomyopathy: Difference between revisions
Jump to navigation
Jump to search
| Line 10: | Line 10: | ||
===Treatment=== | ===Treatment=== | ||
* Atrial fibrillation should be managed with amiodarone | * Atrial fibrillation in the patient with HOCM should be managed with amiodarone | ||
* The medical management of the patient with hypertrophic cardiomyopathy involves minimizing diastolic dysfunction, reducing left ventricular outflow tract obstruction, optimizing [[heart failure]] management, maintaining [[normal sinus rhythm]], rate control and anticoagulation in the presence of [[atrial fibrillation]], and implantation of an [[automatic implantable cardiac defibrillator]] in those patients who survive [[sudden cardiac death]]. | |||
==References== | ==References== | ||
Revision as of 22:49, 31 October 2011
|
Cardiology Overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Hypertrophic Obstructive Cardiomyopathy
Screening
- Athletes should be screened using a family history of sudden death and a murmur on physical examination. Electrocardiograms and echocardiograms are not cost effective in this population.
Prognosis
- The myosin binding proteins C genetic variant carries a good prognosis.
- The presence of VT / VF carries the poorest prognosis. Outflow gradient is also related to prognosis.
Treatment
- Atrial fibrillation in the patient with HOCM should be managed with amiodarone
- The medical management of the patient with hypertrophic cardiomyopathy involves minimizing diastolic dysfunction, reducing left ventricular outflow tract obstruction, optimizing heart failure management, maintaining normal sinus rhythm, rate control and anticoagulation in the presence of atrial fibrillation, and implantation of an automatic implantable cardiac defibrillator in those patients who survive sudden cardiac death.